| 11.9 0.95 (8.68%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.38 |
1-year : | 16.8 |
| Resists | First : | 12.31 |
Second : | 14.38 |
| Pivot price | 11.25 |
|||
| Supports | First : | 10.7 |
Second : | 9.71 |
| MAs | MA(5) : | 10.67 |
MA(20) : | 11.01 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 26.1 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 13.25 | Low : | 9.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARTV ] has closed below upper band by 25.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 12.31 - 12.37 | 12.37 - 12.42 |
| Low: | 10.95 - 11.01 | 11.01 - 11.07 |
| Close: | 11.79 - 11.9 | 11.9 - 12 |
Thu, 29 Aug 2024
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Mon, 22 Jul 2024
Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data (ARTV) - Seeking Alpha
Mon, 22 Jul 2024
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com
Mon, 22 Jul 2024
Artiva Biotherapeutics prices IPO at $167 million - ShareCast
Mon, 22 Jul 2024
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com
Fri, 19 Jul 2024
Artiva Biotherapeutics stock in trading debut (Pending:ARTV) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 24 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 65.3 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 28 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -234.72 |
| Profit Margin | -111.2 % |
| Operating Margin | -108.9 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.2 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -12.8 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 9.87 |
| Price to Cash Flow | -5.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|